RESUMO
Sixty-two subjects having either insulin-dependent or non-insulin-dependent diabetes completed a randomized, double-blind study comparing effects of aspartame or a placebo on blood glucose control. Twenty-nine subjects consumed 2.7 g aspartame per day for 18 wk, given as aspartame-containing capsules with meals, while 33 subjects took identical appearing placebo capsules. After 18 wk, no changes were seen in fasting or 2-h postprandial blood glucose levels or glycohemoglobin levels in either the aspartame- or placebo-treated groups. Adverse reactions were no more common in the group taking aspartame. We conclude that use of aspartame as a low-calorie sweetener does not adversely affect glycemic control of persons with diabetes.
Assuntos
Aspartame/efeitos adversos , Diabetes Mellitus/dietoterapia , Dipeptídeos/efeitos adversos , Adolescente , Adulto , Glicemia/metabolismo , Ensaios Clínicos como Assunto , Diabetes Mellitus/sangue , Método Duplo-Cego , Hemoglobinas Glicadas/análise , Humanos , Pessoa de Meia-Idade , Distribuição Aleatória , SegurançaRESUMO
Aspartame is a dipeptide containing aspartic acid and phenylalanine methyl ester. It is a nutritive sweetener with a caloric value equivalent to that of other proteins and with sweetness approximately 180 times that of sucrose. Thus, for equivalent sweetening power, it contributes only 0.5% of the kilocalories of sugar. Numerous studies have shown no potential toxicity of amounts of aspartame likely to be ingested, or even of abuse doses. Although aspartame cannot fully replace sugar, it appears to be a safe and acceptable sweetener for those who must, or desire to, reduce their intake of sucrose.
